title: Nursing management of MS patients receiving interferon beta-1b therapy.
abstract: In 1993, recombinant interferon beta-1b (Betaseron, Berlex Laboratories) was approved by the Food and Drug Administration as a treatment for relapsing-remitting multiple sclerosis (MS). Betaseron is the first therapeutic agent licensed for use with therapeutic patients with MS in more than 20 years. Many patients and their families have expressed great interest in obtaining information about this agent. In response, MS centers throughout the United States have developed Betaseron training programs. This article describes how rehabilitation nurses can educate patients and families about Betaseron.
authors.affiliation: Department of Neurology, Maryland Center for Multiple Sclerosis, University of Maryland, Baltimore 21201, USA.
authors.forename: K
authors.initials: K
authors.lastname: Costello
authors.forename: K
authors.initials: K
authors.lastname: Conway
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000451:nursing*; D010353:Patient Education as Topic; D019145:Rehabilitation Nursing
chemical_list: D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000068556:Interferon beta-1a